421551-75-9

Basic information

• Product Name: tert-Butyl 4-formylphenethylcarbamate
• Synonyms: carbamic acid, [2-(4-formylphenyl)ethyl]-, 1,1-dimethylethyl ester;Carbamic acid, N-[2-(4-formylphenyl)ethyl]-, 1,1-dimethylethyl ester
• CAS NO: 421551-75-9
• Molecular Formula: C14H19NO3
• Molecular Weight: 249.30556
• EINECS: -0
• Mol File: 421551-75-9.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-Butyl 4-formylphenethylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-formylphenethylcarbamate(421551-75-9)
• EPA Substance Registry System: tert-Butyl 4-formylphenethylcarbamate(421551-75-9)

Safety Data

• Hazardous Substances Data: 421551-75-9(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-formylphenethylcarbamate is a chemical compound that belongs to the carbamate class of chemicals. It is produced using tert-butyl isocyanate and 4-formylphenethylamine. tert-Butyl 4-formylphenethylcarbamate is commonly used as an intermediate in the synthesis of pharmaceuticals or agrochemicals. It has been found to have insecticidal and acaricidal properties, making it useful in pest control applications. Tert-butyl 4-formylphenethylcarbamate is a white solid with a molecular weight of 259.34 g/mol, and its chemical formula is C13H19NO3. It is important to handle this chemical with care and to follow proper safety measures when working with it.

Upstream product

• 56161-89-8 4-(2-aminoethyl)-benzoic acid methyl ester-hydrochloride 
• 1199-69-5 4-(2-aminoethyl)benzoic acid 
• 73918-56-6 4-Bromophenethylamine 
• 120157-97-3 t-butyl 2-(4-bromophenyl)ethylcarbamate 
• 68-12-2 N,N-dimethyl-formamide 
• 132690-91-6 4-[2-(tert-butyloxycarbonylamino)ethyl]benzoic acid 
• 60531-36-4 4-(2-amino-ethyl)-benzoic acid hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 177736-04-8 methyl 4-[2-(tert-butoxycarbonylamino)ethyl]benzoate 
• 421551-76-0 tert-butyl N-{2-[4-(hydroxymethyl)phenyl]ethyl}carbamate 
• 1122-91-4 4-bromo-benzaldehyde 

Relevant articles and documents

PCSK9 ANTAGONIST COMPOUNDS

Disclosed are compounds of Formula (A), or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

PCSK9 ANTAGONIST COMPOUNDS

Disclosed are compounds of Formula I, or a salt thereof: where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

Design and synthesis of novel lactate dehydrogenase a inhibitors by fragment-based lead generation

Lactate dehydrogenase A (LDHA) catalyzes the conversion of pyruvate to lactate, utilizing NADH as a cofactor. It has been identified as a potential therapeutic target in the area of cancer metabolism. In this manuscript we report our progress using fragment-based lead generation (FBLG), assisted by X-ray crystallography to develop small molecule LDHA inhibitors. Fragment hits were identified through NMR and SPR screening and optimized into lead compounds with nanomolar binding affinities via fragment linking. Also reported is their modification into cellular active compounds suitable for target validation work.